Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: A prospective analysis and comparison of two agents

Denise Roe, Antonia M. Harford, Philip G. Zager, Thomas B. Wiltbank, Linda Kirlin, Ann Marie Della Valle, David B. Van Wyck

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

We sought to determine the rate and extent of iron utilization after administration of intravenous iron dextran and to compare the efficacy of iron dextran preparations of differing molecular weight. We randomized patients to receive either a 500-mg dose of iron dextran molecular weight (MW) 267,000 (group A) or iron dextran MW 96,000 (group B) administered in five sequential 100-mg doses, and examined indices of iron status before and at weekly intervals up to 4 weeks later. Although mean iron utilization was greater in the nine group A patients (46.7% ± 21.3%) than in the 11 group B patients (31.7% ± 26.6%), the difference was not statistically significant (P=0.19). Iron utilization in both groups was substantially incomplete. Changes in serum ferritin and hemoglobin did not differ between the treatments (P = 0.49 and P = 0.34, respectively). We conclude that iron utilization after iron dextran administration is substantial within the first week after completing a course of therapy, associated with stable iron indices after the first 2 weeks, and incomplete for at least the first 4 weeks. Degree of iron utilization appears independent of molecular weight within the range we examined.

Original languageEnglish (US)
Pages (from-to)855-860
Number of pages6
JournalAmerican Journal of Kidney Diseases
Volume28
Issue number6
StatePublished - Dec 1996

Fingerprint

Dextrans
Anemia
Dialysis
Iron
Molecular Weight
Ferritins
Intravenous Administration
Hemoglobins

Keywords

  • Anemia
  • bioequivalence
  • dialysis
  • iron
  • iron deficiency
  • kidney disease

ASJC Scopus subject areas

  • Nephrology

Cite this

Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia : A prospective analysis and comparison of two agents. / Roe, Denise; Harford, Antonia M.; Zager, Philip G.; Wiltbank, Thomas B.; Kirlin, Linda; Della Valle, Ann Marie; Van Wyck, David B.

In: American Journal of Kidney Diseases, Vol. 28, No. 6, 12.1996, p. 855-860.

Research output: Contribution to journalArticle

Roe, Denise ; Harford, Antonia M. ; Zager, Philip G. ; Wiltbank, Thomas B. ; Kirlin, Linda ; Della Valle, Ann Marie ; Van Wyck, David B. / Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia : A prospective analysis and comparison of two agents. In: American Journal of Kidney Diseases. 1996 ; Vol. 28, No. 6. pp. 855-860.
@article{22e3ddbceef34f8ba701fce7d2bc7e2d,
title = "Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: A prospective analysis and comparison of two agents",
abstract = "We sought to determine the rate and extent of iron utilization after administration of intravenous iron dextran and to compare the efficacy of iron dextran preparations of differing molecular weight. We randomized patients to receive either a 500-mg dose of iron dextran molecular weight (MW) 267,000 (group A) or iron dextran MW 96,000 (group B) administered in five sequential 100-mg doses, and examined indices of iron status before and at weekly intervals up to 4 weeks later. Although mean iron utilization was greater in the nine group A patients (46.7{\%} ± 21.3{\%}) than in the 11 group B patients (31.7{\%} ± 26.6{\%}), the difference was not statistically significant (P=0.19). Iron utilization in both groups was substantially incomplete. Changes in serum ferritin and hemoglobin did not differ between the treatments (P = 0.49 and P = 0.34, respectively). We conclude that iron utilization after iron dextran administration is substantial within the first week after completing a course of therapy, associated with stable iron indices after the first 2 weeks, and incomplete for at least the first 4 weeks. Degree of iron utilization appears independent of molecular weight within the range we examined.",
keywords = "Anemia, bioequivalence, dialysis, iron, iron deficiency, kidney disease",
author = "Denise Roe and Harford, {Antonia M.} and Zager, {Philip G.} and Wiltbank, {Thomas B.} and Linda Kirlin and {Della Valle}, {Ann Marie} and {Van Wyck}, {David B.}",
year = "1996",
month = "12",
language = "English (US)",
volume = "28",
pages = "855--860",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia

T2 - A prospective analysis and comparison of two agents

AU - Roe, Denise

AU - Harford, Antonia M.

AU - Zager, Philip G.

AU - Wiltbank, Thomas B.

AU - Kirlin, Linda

AU - Della Valle, Ann Marie

AU - Van Wyck, David B.

PY - 1996/12

Y1 - 1996/12

N2 - We sought to determine the rate and extent of iron utilization after administration of intravenous iron dextran and to compare the efficacy of iron dextran preparations of differing molecular weight. We randomized patients to receive either a 500-mg dose of iron dextran molecular weight (MW) 267,000 (group A) or iron dextran MW 96,000 (group B) administered in five sequential 100-mg doses, and examined indices of iron status before and at weekly intervals up to 4 weeks later. Although mean iron utilization was greater in the nine group A patients (46.7% ± 21.3%) than in the 11 group B patients (31.7% ± 26.6%), the difference was not statistically significant (P=0.19). Iron utilization in both groups was substantially incomplete. Changes in serum ferritin and hemoglobin did not differ between the treatments (P = 0.49 and P = 0.34, respectively). We conclude that iron utilization after iron dextran administration is substantial within the first week after completing a course of therapy, associated with stable iron indices after the first 2 weeks, and incomplete for at least the first 4 weeks. Degree of iron utilization appears independent of molecular weight within the range we examined.

AB - We sought to determine the rate and extent of iron utilization after administration of intravenous iron dextran and to compare the efficacy of iron dextran preparations of differing molecular weight. We randomized patients to receive either a 500-mg dose of iron dextran molecular weight (MW) 267,000 (group A) or iron dextran MW 96,000 (group B) administered in five sequential 100-mg doses, and examined indices of iron status before and at weekly intervals up to 4 weeks later. Although mean iron utilization was greater in the nine group A patients (46.7% ± 21.3%) than in the 11 group B patients (31.7% ± 26.6%), the difference was not statistically significant (P=0.19). Iron utilization in both groups was substantially incomplete. Changes in serum ferritin and hemoglobin did not differ between the treatments (P = 0.49 and P = 0.34, respectively). We conclude that iron utilization after iron dextran administration is substantial within the first week after completing a course of therapy, associated with stable iron indices after the first 2 weeks, and incomplete for at least the first 4 weeks. Degree of iron utilization appears independent of molecular weight within the range we examined.

KW - Anemia

KW - bioequivalence

KW - dialysis

KW - iron

KW - iron deficiency

KW - kidney disease

UR - http://www.scopus.com/inward/record.url?scp=0029800438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029800438&partnerID=8YFLogxK

M3 - Article

C2 - 8957037

AN - SCOPUS:0029800438

VL - 28

SP - 855

EP - 860

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 6

ER -